CTRI/2021/03/032021尚未招募未知
A Phase 2b study to determine the efficacy of probiotics given in peritransplant period among allogenic stem cell transplant recipients in preventing gram negative bacteremia, mortality, graft versus host disease
Christian Medical College Vellore0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Age >18 years.
- •2) Undergoing Allogenic Stem cell transplant in the Department of Haematology, CMC Vellore. 3) Presence of CRO or ESBL organism in Pre-transplant Fecal surveillance
排除标准
- •1) Age <18 years
- •2) Susceptible organisms in the Pre-transplant Faecal surveillance.
- •3) Patients who already have an ongoing bacterial infection at the time of HSCT.
研究者
相似试验
招募中
2 期
A phase II study to evaluate the effectiveness of S-1 + Cetuximab for patients with advanced/recurrent colon cancer who cannot undergo intensive therapyadvanced/recurrent colon cancer patients with RAS wild-type tumors who cannot undergo intensive therapyJPRN-UMIN000018484HO HOKKAIDO CANCER CENTER Division of Gastroenterology57
招募中
不适用
The study evaluate the efficacy of intraoperative radiotherapy those who underwent neoadjuvant chemotherapy for pancreatic cancer.KCT0005113Yonsei University Health System, Gangnam Severance Hospital80
进行中（未招募）
1 期
VAC071: A study to assess efficacy of the ChAd63/MVA PvDBP vaccinesPlasmodium vivax malariaMedDRA version: 20.0Level: LLTClassification code 10047665Term: Vivax malaria (benign tertian)System Organ Class: 100000004862EUCTR2019-000643-27-GBniversity of Oxford / Clinical Trials and Research Governance19
已完成
2 期
A phase II study to investigate the efficacy of neoadjuvant erlotinib in patients with clinical stage I/II non-small cell lung cancer (NSCLC)early stage lung cancernon-small cell lung cancer stage I/II10038666NL-OMON29708Antoni van Leeuwenhoek Ziekenhuis55
已完成
2 期
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50